FDA
-
-
-
-
-
-
-
NuCana to Participate in Two Upcoming Investor Conferences
-
-
-
-
-
-
-
NuCana to Present at the Jefferies 2021 London Healthcare Conference
-
-
-
-
-
-
-
NuCana Receives Fast Track Designation from the U.S. Food and Drug Administration for Acelarin® (NUC-1031) for the Treatment of Biliary Tract Cancer
-
-
-
-
-
-
-
NuCana (NCNA) Adds Andrew Kay as Board Chair
-
-
-
-
-
-
-
Pre-Open Movers 09/17: (SRNE) (MLHR) (RIGL) Higher; (SBBP) (NCNA) (SNOW) Lower (more...)
-
-
-
-
-
-
-
NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update
-
-
-
-
-
-
-
NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

